Drug Profile

Vicadrostat - Boehringer Ingelheim

Alternative Names: BI-690517; C 14

Latest Information Update: 02 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Class 2 ring heterocyclic compounds; Alcohols; Benzonitrile; Chlorinated hydrocarbons; Imidazoles; Pyrones; Small molecules; Urologics
Mechanism of Action Cytochrome P-450 CYP11B2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase III Cardiovascular disorders; Heart failure; Hypertension; Renal failure; Type 2 diabetes mellitus
No development reported Diabetic nephropathies

21 Aug 2025 Boehringer Ingelheim plans a phase I trial (In volunteers, Combination therapy) in Germany (NCT07133399)
15 Aug 2025 Boehringer Ingelheim completes a phase I bioavailability trial (In volunteers) in Germany (PO) (NCT07035457)
24 Jul 2025 Boehringer Ingelheim plans a phase III trial for Type II diabetes mellitus, Hypertension and Cardiovascular diseases (Combination therapy) in USA, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey and Vietnam in July 2025 (NCT07064473) (EudraCT2025-521188-11-00)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com